Faculty Publications

As of August 2017, this database is no longer being updated. For the most current publications from the faculty, students, and staff of Touro University, please check our institutional repository, Touro Scholar, and email any questions or publication submissions to touro.scholar@touro.edu.

Total number of publications: 7,082

Enter a faculty name:

or browse faculty by school:

Administrative Offices

Graduate Schools

Health Sciences

Lander Colleges

Law Center

New York School of Career and Applied Studies (NYSCAS)

Touro University System

Reset
First Prev 1 2 3 4 Next Last

  • Lynch, K., Venugopalan, V., & Hidayat, L. (2014). The effect of diabetes mellitus on the clinical and micro-biological outcomes in patients with acute pyelonephritis. American Journal of Infectious Diseases, 10(2), 71-76. doi:10.3844/ajidsp.2014.71.76

    		•

  • Miller, E., & Shubrook, J. H. (2015). Sodium glucose co-transporter 2 inhibitors in the treatment of Type 2 diabetes mellitus. Osteopathic Family Physician, 7(5), 10-30. This material can be found here.

  • Millstein, R., Becerra, N. M., & Shubrook, J. H. (2015). Insulin pumps: Beyond basal-bolus. Cleveland Clinic Journal of Medicine, 82(12), 835-842. This material can be found here.

  • Morris, M. R., Ludwar, B. C., Swingle, E., Mamo, M. N., & Shubrook, J. H. (2016). A new method to assess asymmetry in fingerprints could be used as an early indicator of type 2 diabetes mellitus. Journal of Diabetes Science and Technology, 10(4), 864-871. doi:10.1177/1932296816629984

    		•

  • Nguyen, Q. T. (2015). Adherence to antihyperglycemic treatment regimen also reduces overall costs. American Health & Drug Benefits, 8(3), 157-158. This material can be found here.

  • Nguyen, Q. T. (2015). Evaluating the benefits and cost of the sodium-glucose cotransporter 2 inhibitors. American Health & Drug Benefits, 8(6). This material can be found here.

  • Pandya, K. A., Firestone, R., Parker, P., & Duby, J. J. (2014). Enhancing quality and safety in insulin therapy: A multidisciplinary approach to create and validate continuous infusion insulin protocols [Supplemental material]. American Journal of Medical Quality, 29(2), 23S. doi:10.1177/1062860613519567

    		•

  • Patel, M. R., Pandya, K. G., Lau-Cam, C. A., Singh, S., Pino, M. A., Billack, B., . . . Degenhardt, K. (2012). Design and synthesis of N-Substituted Indazole-3-Carboxamides as Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Chemical Biology & Drug Design, 79(4), 488-496.  doi:10.1111/j.1747-0285.2011.01302.x

    		•

  • Plodkowski, R. A., McGarvey, M. E., Huribal, H. M., Reisinger-Kindle, K., Kramer, B., Solomon, M., & Nguyen, Q. T. (2015). SGLT-2 inhibitors for the treatment of type 2 diabetes mellitus. Federal Practitioner, 32(Suppl. 11), 10S-17S. This material can be found here.

  • Presswala, L., & Shubrook, J. H. (2015). What to do after basal insulin: 3 Tx strategies for type 2 diabetes. Journal of Family Practice, 64(4), 214-220. This material can be found here.

  • Rao, M. N., Neylan, T. C., Grunfeld, C., Mulligan, K., Schambelan, M., & Schwarz, J. M. (2015). Subchronic sleep restriction causes tissue-specific insulin resistance. Journal of Clinical Endocrinology & Metabolism, 100(4), 1664-1671. doi:10.1210/jc.2014-3911

    		•

  • Rosenfeld, C. R. (2013). Insulin therapy in type 2 diabetes mellitus: history drives patient care toward a better future. Journal of the American Osteopathic Association, 113(4 Suppl. 2), S4-5. This material can be found here.

  • Rosenfeld, C. R. (2016). Treatment of pasireotide LAR-associated hyperglycemia in a patient with acromegaly. Endocrine Practice, 22(Suppl. 2), 213-214. doi:10.4158/1530-891X-22.s2.193

    		•

  • Rosenfeld, C. R., Bohannon, N., Bode, B., Kelman, A., Mintz, S., Schorr, A., . . . Strange, P. (2012). The V-Go insulin delivery device used in clinical practice: Patient perception and retrospective analysis of glycemic control. Endocrine Practice, 18(5), 660-667. doi:10.4158/EP11362.OR

    		•

  • Santana, R. B., Xu, L., Chase, H. B., Amar, S., Graves, D. T., & Trackman, P. C. (2003). A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes, 52(6), 1502-1510. doi:10.2337/diabetes.52.6.1502

    		•

  • Scheinberg, N., Salbu, R. L., Goswami, G., & Cohen, K. R.(2016). Treatment of diabetic autonomic neuropathy in older adults with diabetes mellitus. Consultant Pharmacist, 31(11), 633-645. doi:10.4140/TCP.n.2016.633

    		•

  • Schwarz, J. M., Noworolski, S. M., Wen, M. J., Dyachenko, A., Prior, J. L., Weinberg, M. E., . . . Bergeron, N. (2015). Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat. Journal of Clinical Endocrinology & Metabolism, 100(6), 2434-2442. doi:10.1210/jc.2014-3678

    		•

  • Shah, B. M., Gupchup, G. V., Borrego, M. E., Raisch, D. W., & Knapp, K. K. (2012). Depressive symptoms in patients with type 2 diabetes mellitus: Do stress and coping matter? Stress and Health, 28(2), 111–122. doi:10.1002/smi.1410

    		•

  • Shah, B. M., Mezzio, D. J., Ho, J., & Ip, E. J. (2015). Association of ABC (HbA1c, blood pressure, LDL-cholesterol) goal attainment with depression and health-related quality of life among adults with type 2 diabetes. Journal of Diabetes and Its Complications, 29(6), 794-800. doi:10.1016/j.jdiacomp.2015.04.009

    		•

  • Shubrook, J. H., Bokaie, B. B., & Adkins, S. E. (2015). Empagliflozin in the treatment of type 2 diabetes: Evidence to date. Drug Design, Development and Therapy, 9, 5793-5803. doi:10.2147/DDDT.S69926

    		•

  • Shubrook, J. H., Brown, H., Lang, M., & Berryman, D. (2015). Patient preferences for diabetes education. Journal of the American Osteopathic Association, 115(12), e87-e88. This material can be found here.

  • Shubrook, J. H., deGroot, M., Pillay, Y., Hornsby, G., Saha, C., & Mather, K. (2015). Program ACTIVE II: Testing behavioral interventions for depression in T2DM. Journal of the American Osteopathic Association, 115(12), e100-e101. This material can be found here.

  • Skolnik, N., Jaffa, F. M., Kalyani, R. R., Johnson, E., & Shubrook, J. H. (2017). Reducing CV risk in diabetes: An ADA update. Journal of Family Practice, 66(5), 300-308. This material can be found here.

  • Stanhope, K. L., Schwarz, J. M., & Havel, P. J. (2013). Adverse metabolic effects of dietary fructose: Results from the recent epidemiological, clinical, and mechanistic studies. Current Opinion in Lipidology, 24(3), 198-206.  doi:10.1097/MOL.0b013e3283613bca

    		•

  • Steinman, G. D., (2013). The proposed role of insulin-like growth factor-1 in autism: A review. OA Autism, 1(2) [Article 20]. This material can be found here.

First Prev 1 2 3 4 Next Last